Profil
Marina Udier currently works at Nouscom AG, as Chief Executive Officer & Director from 2020, Nouscom Srl, as Chief Executive Officer & Director, and Celyad Oncology SA, as Independent Director from 2011.
Dr. Udier also formerly worked at Novartis AG, as Head-Global Commercial and Versant Venture Management LLC, as Chief Operating Officer.
Dr. Udier received her doctorate degree from Yale University.
Postes actifs de Marina Udier
| Sociétés | Poste | Début |
|---|---|---|
| CELYAD ONCOLOGY SA | Directeur/Membre du Conseil | 11/01/2011 |
Nouscom AG
Nouscom AG Pharmaceuticals: MajorHealth Technology Operates as an oncology company that develops immunotherapies | Directeur Général | 01/05/2019 |
Nouscom Srl
Nouscom Srl Miscellaneous Commercial ServicesCommercial Services Operates as a next-generation immunotherapy company that develops engineered viral vectored vaccines for treatment of cancer | Directeur Général | - |
Anciens postes connus de Marina Udier
| Sociétés | Poste | Fin |
|---|---|---|
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Ventures invests in biotechnology companies located globally. The firm participates in early and later stage capital requirements. | Directeur des opérations | - |
| NOVARTIS AG | Corporate Officer/Principal | - |
Formation de Marina Udier
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Novartis AG
Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Ventures invests in biotechnology companies located globally. The firm participates in early and later stage capital requirements. | Finance |
Celyad Oncology SA
Celyad Oncology SA BiotechnologyHealth Technology Develops immuno-oncology and cardiology products | Health Technology |
Nouscom AG
Nouscom AG Pharmaceuticals: MajorHealth Technology Operates as an oncology company that develops immunotherapies | Health Technology |
Nouscom Srl
Nouscom Srl Miscellaneous Commercial ServicesCommercial Services Operates as a next-generation immunotherapy company that develops engineered viral vectored vaccines for treatment of cancer | Commercial Services |
















